Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

UK SMA Patient Registry

Sponsor: Newcastle University

NCT ID: NCT04292574

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Patient Registry (other)
How long the study runs
Study runs about 378 months (dates as stated)
About the drug or intervention
Patient Registry — other: Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
Not specified
Who
All
Number of participants
800
Started
2008-07-13
Last checked
2026-08

Plain English Summary

What is this study?

  • • Testing a new treatment for spinal muscular atrophy
  • • Clinical study - 800 participants
  • • Spinal muscular atrophy (SMA) is a form of motor neuron disease, most commonly caused by a mutation in the survival motor neuron 1 gene (SMN1) which results in a wide disease spectrum affecting children and adults

Who can take part?

  • • Adults
  • • Diagnosed with spinal muscular atrophy

Where?

  • • Newcastle upon Tyne - John Walton Muscular Dystrophy Research Centre

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Spinal muscular atrophy (SMA) is a form of motor neuron disease, most commonly caused by a mutation in the survival motor neuron 1 gene (SMN1) which results in a wide disease spectrum affecting children and adults. It is an autosomal recessive disorder and is therefore caused by inheritance of a mutated gene from each parent. All forms of SMA have an estimated combined incidence of 1 in 6,000 to 1 in 10,000 live births, with a carrier frequency of 1/40 to 1/60. The patient registry aims to facilitate a questionnaire-based research study in order to better characterise and understand the disease in the UK and in Ireland. Entry is via self-registration over a secure internet connection (https://www.sma-registry.org.uk/). Online, patients are asked to read an information sheet about the research project and then indicate their consent to demonstrate willingness to participate. Following online consent, subjects will be entered into the registry. This is an on-going database and all participants are invited to update their information on a biannual basis.

More detail

Participants are asked to provide information by completing online questionnaires. The medical questionnaire asks specific questions about their SMA diagnosis and their condition, including their motor function, requirement of assistance for feeding or breathing, scoliosis, contractures, hospitalisations, other illnesses, medications and participation in clinical trials. Additional short questionnaires collect information about patients' experience of daily life, their activities and quality of life, also known as patient-reported outcome measures or PROMs. Participants are asked to forward a copy of their genetic results to the registry. The registry collaborates closely with the clinical networks SMA REACH UK (paediatric) and Adult SMA REACH and with TREAT-NMD Alliance. The SMA REACH networks collect clinician-reported medical and functional assessment data from consented SMA patients who attend participating neuromuscular clinics in the UK. Links between the SMA REACH clinical databases and the UK SMA Patient Registry have been developed to enable the consented sharing of limited and specific data. Currently, linkage enables the sharing of patient-level PROMs data collected by the registry with each patient's SMA REACH clinic and with the SMA REACH coordination teams. At clinic level, the data informs patient care. At project coordination level, the data is aligned with clinical data collected by SMA REACH. It is then anonymised, analysed and reported to regulatory authorities as part of managed access agreements (MAA) for SMA therapies. Future linkage will enable patient registry participants to view elements of their own clinical data entered into the SMA REACH database by their doctor.

Spinal Muscular AtrophySMA

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: Not specified
  • Who can join: All genders

What the study is looking for

  • ✓All patients with a confirmed SMA diagnosis (or pending diagnosis) are eligible for inclusion. Diagnosis will be...

Who cannot take part

  • ✗There are no exclusion criteria for the registry
See the full criteria
Inclusion Criteria: * All patients with a confirmed SMA diagnosis (or pending diagnosis) are eligible for inclusion. Diagnosis will be confirmed via genetic testing results Exclusion Criteria: * There are no exclusion criteria for the registry

Where Is This Study? (1 UK site)

John Walton Muscular Dystrophy Research Centre

Newcastle upon Tyne NE1 3BZ, United Kingdom

Recruiting
Site contact (verified)
Chiara Marini-Bettolo, MD, PhDPrincipal Investigator
Patient Registry manager and curator0191 2418640smaregistry@newcastle.ac.uk
Patient Registry Teamregistries@newcastle.ac.uk

How to Get in Touch

Patient Registry manager and curator

Sponsor contact

CONTACT

0191 2418640 smaregistry@newcastle.ac.uk

Chiara Patient Registry Team

Sponsor contact

CONTACT

registries@newcastle.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2026-08